Author: Ianevski, Aleksandr; Yao, Rouan; Fenstad, Mona Høysæter; Biza, Svetlana; Zusinaite, Eva; Reisberg, Tuuli; Lysvand, Hilde; Løseth, Kirsti; Landsem, Veslemøy Malm; Malmring, Janne Fossum; Oksenych, Valentyn; Erlandsen, Sten Even; Aas, Per Arne; Hagen, Lars; Pettersen, Caroline H.; Tenson, Tanel; Afset, Jan Egil; Nordbø, Svein Arne; Bjørås, Magnar; Kainov, Denis E.
Title: Potential antiviral options against SARS-CoV-2 infection Cord-id: ucqago27 Document date: 2020_6_4
ID: ucqago27
Snippet: As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6,5 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectru
Document: As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6,5 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that combinations of virus-directed nelfinavir along with host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
Search related documents:
Co phrase search for related documents- accession number and lower upper: 1
- accession number and lung cancer: 1, 2
- activity threshold and acute respiratory infection: 1
- acute respiratory infection and additional value: 1, 2
- acute respiratory infection and long term response: 1, 2, 3, 4
- acute respiratory infection and lower upper: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- acute respiratory infection and lung adenocarcinoma: 1, 2, 3
- acute respiratory infection and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute respiratory infection and lung carcinoma: 1
- additional value and lung cancer: 1
- long term response and lower upper: 1
- long term response and lung adenocarcinoma: 1, 2
- long term response and lung cancer: 1
- long term response and lung carcinoma: 1
- lower upper and lung cancer: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date